메뉴 건너뛰기
Neurology
Volumn 74, Issue 2, 2010, Pages 181-
Bevacizumab and irinotecan for recurrent oligodendroglial tumors

(1)  Chamberlain, Marc C a  

a NONE
Author keywords

[No Author keywords available]
Indexed keywords

BEVACIZUMAB; IRINOTECAN;
EID: 75649124562     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181c775e3     Document Type: Letter
Times cited : (3)
References (5)
  • 1
    • 67649410669 scopus 로고    scopus 로고
    • Bevacizumab and irinotecan for recurrent oligodendroglial tumors
    • Tallibert S, Vincent LA, Granger B, et al. Bevacizumab and irinotecan for recurrent oligodendroglial tumors. Neurology 2009;72:1601-1606.
    • (2009) Neurology , vol.72 , pp. 1601-1606
    • Tallibert, S.1    Vincent, L.A.2    Granger, B.3
  • 2
    • 58149470640 scopus 로고    scopus 로고
    • Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma
    • Chamberlain MC, Johnston S. Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma. J Neurooncol 2009;91:359-367.
    • (2009) J Neurooncol , vol.91 , pp. 359-367
    • Chamberlain, M.C.1    Johnston, S.2
  • 3
    • 65249083423 scopus 로고    scopus 로고
    • Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma
    • Chamberlain MC, Johnston S. Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma. Cancer 2009;115:1734-1743.
    • (2009) Cancer , vol.115 , pp. 1734-1743
    • Chamberlain, M.C.1    Johnston, S.2
  • 4
    • 41649112610 scopus 로고    scopus 로고
    • Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence
    • Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008;70:779-787.
    • (2008) Neurology , vol.70 , pp. 779-787
    • Norden, A.D.1    Young, G.S.2    Setayesh, K.3
  • 5
    • 58149231546 scopus 로고    scopus 로고
    • Bevaci-zumab plus irinotecan in recurrent WHO grade 3 malignant gliomas
    • Desjardins AII, Reardon DA, Herndon JE, et al. Bevaci-zumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res 2008;14:7068-7073.
    • (2008) Clin Cancer Res , vol.14 , pp. 7068-7073
    • Desjardins, A.I.I.1    Reardon, D.A.2    Herndon, J.E.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.